Missouri is currently home to 1896 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Saint Louis, Kansas City, St. Louis and Springfield. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers
NCT05616624
Recruiting
In this study, patients with small cell or non-small cell lung cancer will receive ADI-PEG 20, gemcitabine, and docetaxel after demonstrated progression on frontline therapy. In phase I of the study, up to 6 dose levels will be tested to find the recommended phase II dose (RP2D), after which patients enrolling to phase II will be treated at that dose level to assess efficacy. Although safety and tolerability has been previously determined in the sarcoma population, dose de-escalations of the che... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Non Small Cell Lung Cancer, Non-small Cell Lung Cancer, Small-cell Lung Cancer, Small Cell Lung Carcinoma
Register for Updates
Patients At Risk for Sensory Screening (HPARSS) to Enhance Sensory Deficit Screening in Childhood Cancer Survivors
NCT05582551
Recruiting
The overall goal of this study is to attempt to overcome the organizational barriers that impede prompt screening for at-risk sensory deficits in childhood cancer survivors (CCS). Using a cross sectional design study, collaborators in the Informatics Research branch of the Institute of Informatics at the Washington University School of Medicine will identify CCS at risk for sensory deficits based upon their therapy exposure to generate the highlighting patients at risk for sensory screening (HPA... Read More
Gender:
ALL
Ages:
Between 7 years and 17 years
Trial Updated:
04/28/2025
Locations: St. Louis Children's Hospital - Washington University School of Medicine, Saint Louis, Missouri
Conditions: Childhood Cancer
Register for Updates
Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
NCT04202341
Recruiting
Long-term, multicenter, multinational, observational, registry of patients with gMG that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT) such as eculizumab (Soliris®) and ravulizumab (Ultomiris®).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: Clinical Trial Site, Columbia, Missouri
Conditions: Generalized Myasthenia Gravis
Register for Updates
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
NCT06767514
Recruiting
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Clinical Study Site, Kansas City, Missouri
Conditions: Non-Small Cell Lung Cancer
Register for Updates
AZD0486 as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
NCT06526793
Recruiting
This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of AZD0486 monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who have received at least two prior lines of therapies. The study has 2 Modules: Module 1 for FL and Module 2 for DLBCL.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/25/2025
Locations: Research Site, Saint Louis, Missouri
Conditions: B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL)
Register for Updates
Study of IK-595 in RAS- or RAF-altered Advanced Tumors
NCT06270082
Recruiting
This is a Phase 1, FIH, Dose Escalation and Dose Expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) effects, and preliminary antitumor activity of IK-595, a MEK/RAF molecular glue, administered orally as monotherapy in patients with advanced solid tumors with gene alterations in the RAS- MAPK pathway for whom there are no further treatment options known to confer clinical benefit.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Washington University School of Medicine, St. Louis, Missouri
Conditions: Solid Tumor, Adult, Colorectal Cancer, Pancreatic Cancer, Malignant Melanoma, Ras (Kras or Nras) Gene Mutation, BRAF Gene Mutation, CRAF Gene Mutation, Non-Small Cell Lung Carcinoma, Thyroid Carcinoma, Gliomas, Malignant
Register for Updates
Intraamniotic Administrations of ER004 to Male Subjects With X-linked Hypohidrotic Ectodermal Dysplasia
NCT04980638
Recruiting
This is an open-label, prospective, genotype-match controlled for primary estimand, non randomized, multicenter, international Phase 2 clinical trial designed to investigate the efficacy and safety of ER004 administered intraamniotically as a treatment for unborn XLHED male subjects.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Washington University, St. Louis, Missouri
Conditions: X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)
Register for Updates
C-Brace Prospective Registry
NCT04640584
Recruiting
To gather prospective safety and effectiveness data for the C-Brace System following the standard of care.
Gender:
ALL
Ages:
All
Trial Updated:
04/25/2025
Locations: P&O Care x Ottobock.care, Saint Louis, Missouri
Conditions: Pareses, Lower Extremity
Register for Updates
Master Protocol for Evaluating Multiple Infection Diagnostics for Ciprofloxacin-Resistant Neisseria Gonorrhoeae
NCT06815536
Recruiting
The goal of this study is to learn if a few investigational tests can correctly find the gene mutation (mutant allele gyrA 91F) that predicts ciprofloxacin resistance in clinical specimens that harbor Neisseria gonorrhoeae. The main question the study aims to answer: Can the investigational reflex test find the correct gene mutation (Neisseria gonorrhoeae gyrA 91F or gyrA 91S) as compared to the sequenced result? Specimens that are collected for routine clinical care and harbor Neisseria gonor... Read More
Gender:
ALL
Ages:
All
Trial Updated:
04/24/2025
Locations: Corewell Health, Royal Oak, Missouri
Conditions: Neisseria Gonorrheae Infection
Register for Updates
PREEMIE: Study for Treatment of PDA in Premature Infants
NCT06587282
Recruiting
This multicenter, single arm, prospective, non-randomized study is designed to evaluate the safety and effectiveness of The Bloom Micro Occluder System for the treatment of patent ductus arteriosus (PDA) in pre-mature infants over a period of 6 months.
Gender:
ALL
Ages:
5 days and above
Trial Updated:
04/24/2025
Locations: Washington University-St. Louis Children's Hospital, Saint Louis, Missouri
Conditions: Patent Ductus Arteriosus (PDA)
Register for Updates
Study of Single Doses of SBT777101 in Subjects With Hidradenitis Suppurativa
NCT06361836
Recruiting
This study will test the safety and effects of SBT777101 when given as a single dose to subjects with hidradenitis suppurativa. Increasing dose levels will be given after the safety at lower dose levels is shown.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/24/2025
Locations: SLUCare Academic Pavillion, Saint Louis, Missouri
Conditions: Hidradenitis Suppurativa
Register for Updates
Evaluate REC-4881 in Patients With FAP
NCT05552755
Recruiting
This is a multicenter, two-part trial in participants with Familial Adenomatous Polyposis (FAP).
Gender:
ALL
Ages:
55 years and above
Trial Updated:
04/24/2025
Locations: Washington University School of Medicine, St. Louis, Missouri
Conditions: Familial Adenomatous Polyposis
Register for Updates